Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0085383 (
hypocapnia
)
1,697
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Recent clinical trial research suggests that baseline low end-tidal CO
2
(ETCO
2
, the biological marker of hyperventilation) may predict poorer response to cognitive-behavioral therapy (CBT) for anxiety-related disorders. The present study examined the predictive value of baseline ETCO
2
among patients treated for such disorders in a naturalistic clinical setting. Sixty-nine adults with a primary diagnosis of a DSM-5 anxiety disorder, obsessive-compulsive disorder, or
posttraumatic stress disorder
completed a 4-min assessment of resting ETCO
2
, and respiration rate (the first minute was analyzed). Lower ETCO
2
was not associated with a diagnosis of panic disorder, and was associated with lower subjective distress ratings on certain measures. Baseline ETCO
2
significantly predicted treatment dropout: those meeting cutoff criteria for
hypocapnia
were more than twice as likely to drop out of treatment, and ETCO
2
significantly predicted dropout beyond other pre-treatment variables. Weekly measurement suggested that the lower-ETCO
2
patients who dropped out were not responding well to treatment prior to dropout. The present results, along with previous clinical trial data, suggest that lower pre-treatment ETCO
2
is a negative prognostic indicator for CBT for anxiety-related disorders. It is suggested that patients with lower ETCO
2
might benefit from additional intervention that targets respiratory abnormality.
...
PMID:Low pre-treatment end-tidal CO
2
predicts dropout from cognitive-behavioral therapy for anxiety and related disorders. 2796 95
